|
|
Article: Wyeth Renews Subscription to Gene Logic's BioExpress System.
- Article from:
- Business Wire
- Article date:
- May 28, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
GAITHERSBURG, Md.--(BUSINESS WIRE)--May 28, 2003
Gene Logic Inc. (Nasdaq:GLGC) today announced that the global pharmaceutical company Wyeth (NYSE: WYE) has renewed its subscription agreement for access to Gene Logic's BioExpress(TM) System.
Financial details of the multiyear renewal agreement were not disclosed.
Commenting on the renewal agreement, Mark D. Gessler, Chairman and CEO of Gene Logic, said, "Wyeth has an extensive drug discovery and development program. The renewal demonstrates that Wyeth continues to focus on what matters most to their business success--identifying promising lead ...